insulinlike growth factor also called somatomedin c hormone similar molecular structure insulin plays important role childhood growth anabolic effects adults protein humans encoded consists amino acids single chain three intramolecular disulfide bridges molecular weight dogs ancient mutation primary cause toy produced primarily liver production stimulated growth hormone gh bound one binding proteins igfbp regulated insulin produced throughout life highest rates production occur pubertal growth lowest levels occur infancy old synthetic analog mecasermin used children treatment growth cyclic glycineproline cgp metabolite hormone insulinlike growth cyclic structure lipophilic nature enzymatically stable makes favourable candidate manipulating bindingrelease process binding protein thereby normalising function produced primarily liver endocrine hormone well target tissues paracrineautocrine fashion production stimulated growth hormone gh retarded growth hormone insensitivity lack growth hormone receptors failures downstream signaling pathway post gh receptor including approximately always bound one binding proteins igfbp abundant protein accounts igf binding binds molar ratio regulated produced throughout life highest rates production occur pubertal growth spurt lowest levels occur infancy old agemedical citation protein intake increases levels humans independent total calorie factors known cause variation levels growth hormone gh circulation include insulin levels genetic makeup time day age sex exercise status stress levels nutrition level body mass index bmi disease state ethnicity estrogen status xenobiotic primary mediator effects growth hormone gh growth hormone made anterior pituitary gland released blood stream stimulates liver produce stimulates systemic body growth growthpromoting effects almost every cell body especially skeletal muscle cartilage bone liver kidney nerve skin hematopoietic lung cells addition insulinlike effects also regulate cellular dna binds least two cell surface receptor tyrosine kinases receptor insulin receptor primary action mediated binding specific receptor present surface many cell types many tissues binding initiates intracellular signaling one potent natural activators akt signaling pathway stimulator cell growth proliferation potent inhibitor programmed cell death receptor seems physiologic receptor binds significantly higher affinity insulin receptor activates insulin receptor approximately times potency insulin part signaling may via receptor heterodimers reason confusion binding studies show binds insulin receptor less well insulin yet correlate actual potency vivo inducing phosphorylation insulin receptor hypoglycemiamedical citation needed binds activates receptor cell surface expression receptor tyrosine kinases signal multiple intracellular transduction cascades critical roleplaying inducer modulating metabolic effects cellular senescence survival localized target cell elicits mediation paracrine activity activation initiation intracellular signaling occurs inducing magnitude signaling pathways important mechanistic pathway involved mediating cascade affect key pathway regulated kinase downstream partner mtor mammalian target rapamycin binds enzyme inhibit complex remains unaffected responds upregulating akt driving signals inhibited phosphorylation eukaryotic translation initiation factor mtor suppresses capacity eukaryotic translation initiation factor protein inhibit slow mutation signaling pathway big factor formation tumors found predominantly skin internal organs secondary lymph nodes kaposi allows activation signaling pathways subsequently regulates cellular longevity metabolic reuptake biogenic substances therapeutic approach targeting towards reduction tumor collections could induced ganitumab ganitumab monoclonal antibody mab directed antagonistically ganitumab binds preventing binding subsequent triggering signaling pathway inhibition prosurvival pathway may result inhibition tumor cell expansion induction tumor cell apoptosiscitation needed insulinlike growth factor shown bind interact seven binding proteins igfbps citation needed igfbps inhibitory example bind higher affinity binds receptor therefore increases serum levels two igfbps result decrease activitymedical citation needed major growth factor responsible stimulating growth cell types including cancer cells causing significant metabolic one important metabolic effect ability signal cells sufficient nutrients available cells undergo hypertrophy cell signals also enable inhibit cell apoptosis increase production cellular receptors ubiquitous allows metabolic changes caused occur cell metabolic effects farreaching coordinate protein carbohydrate fat metabolism variety different cell regulation metabolic effects target tissues also coordinated hormones growth hormone closely related second protein called also binds receptor however alone binds receptor called receptor also called phosphate receptor insulinlike growth factorii receptor lacks signal transduction capacity main role act sink make less available binding name insulinlike growth factor implies structurally related insulin even capable binding insulin receptor albeit lower affinity insulin splice variant sharing identical mature region different e domain known mechanogrowth factor patients severe primary insulinlike growth deficiency igfd called laron syndrome may treated either alone combination mecasermin brand name increlex synthetic analog approved treatment growth rare diseases characterized inability make respond produce distinctive type growth failure one disorder termed laron dwarfism respond growth hormone treatment due lack gh receptors fda grouped diseases disorder called severe primary igf deficiency patients severe primary igfd typically present normal high gh levels height standard deviations sd levels sd severe primary igfd includes patients mutations gh receptor postreceptor mutations igf mutations previously described result patients expected respond gh treatment people laron syndrome low rates cancer notably people untreated laron syndrome also never develop acromegaly syndrome results anterior pituitary gland producing excess growth hormone gh number disorders may increase pituitarys gh output although commonly involves tumor called pituitary adenoma derived distinct type cell somatotrophs leads anatomical changes metabolic dysfunction caused elevated gh elevated high level acromegaly related increased risk cancers particularly colon cancer thyroid mutation signalling pathway factor formation tumors found predominantly skin internal organs secondary lymph nodes kaposi levels measured blood ngml levels fluctuate greatly throughout day individual person used physicians screening test growth hormone deficiency excess acromegaly gigantism interpretation levels complicated wide normal ranges marked variations age sex pubertal stage clinically significant conditions changes may masked wide normal ranges sequential measurement time often useful management several types pituitary disease undernutrition growth problems suggested consumption dairy products could increase cancer risk particularly prostate however review committee carcinogenicity chemicals food consumer products environment coc concluded insufficient evidence draw firm conclusions whether exposure dietary associated increased incidence cancer certain dairy processes fermentation known significantly decrease review found high low levels increase mortality risk whilst ngml associated lowest increased levels associated lower risk cardiovascular disease ischaemic several companies evaluated administering recombinant clinical trials type diabetes type diabetes amyotrophic lateral severe burn injury myotonic muscular dystrophy results clinical trials evaluating efficacy type diabetes type diabetes showed reduction hemoglobin levels daily insulin consumptionmedical citation needed however sponsor discontinued program due exacerbation diabetic coupled shift corporate focus towards oncology two clinical studies als conducted although one study demonstrated efficacy second equivocalmedical citation needed product submitted approval fda called sulfation factor stimulated sulfation cartilage due effects termed nonsuppressible insulinlike activity nsila threedimensional structure human insulinlike growth factori igfi determined distance geometry structures human insulinlike growth factor esrf data human insulinlike growth factor inhouse data human insulinlike growth factor hamburg data human insulinlike growth factor srs daresbury data complex igfi angstrom crystal structure insulinlike growth factori bound phagederived peptide structural basis regulation insulinlike growth factors igfs igf binding proteins igfbps structural basis inhibition insulinlike growth factors igf binding proteins structural basis inhibition insulinlike growth factors igf binding proteins structural basis inhibition insulinlike growth factors igf binding proteins solution structure human insulinlike growth factor nuclear magnetic resonance restrained molecular dynamics study solution structure human insulinlike growth factor nuclear magnetic resonance restrained molecular dynamics study solution structure backbone dynamics growth factori